arrow
P

Pilar Navarro

CSIC
H指数:36
被引数:5,298

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

PARP2 deficiency impairs pancreatic cancer progression by promoting genomic instability and antitumor immunity

PARP2 缺乏通过促进基因组不稳定性和抗肿瘤免疫来抑制胰腺癌进展

2026-05-080
OA
Changes In Serum CXCL13 Levels Are Associated With Outcomes of Colorectal Cancer Patients Undergoing First-Line Oxaliplatin-Based Treatment
2024-07-013
OAAI
The Leukocyte Activation Receptor CD69 Controls T Cell Differentiation through Its Interaction with Galectin-1

白细胞活化受体CD69通过与Galectin-1相互作用控制T细胞分化

2023-03-2085
OA
Gal-1 Expression Analysis in the GLIOCAT Multicenter Study: Role as a Prognostic Factor and an Immune-Suppressive Biomarker
CELLS
IF5.2
2023-03-081
OAAI
Long-term platinum-based drug accumulation in cancer-associated fibroblasts promotes colorectal cancer progression and resistance to therapy
2023-02-1038
OAAI
Soluble AXL is a novel blood marker for early detection of pancreatic ductal adenocarcinoma and differential diagnosis from chronic pancreatitis

可溶性AXL是早期检测胰腺导管腺癌和慢性胰腺炎鉴别诊断疾病的新型血液标志物

2022-01-0129
OAAI
CPEB alteration and aberrant transcriptome-polyadenylation lead to a treatable SLC19A3 deficiency in Huntington's disease

CPEB改变和异常转录组聚腺苷酸化导致亨廷顿氏病可治疗的SLC19A3缺乏症

2021-09-2912
OA
CPEB ALTERATION AND ABERRANT TRANSCRIPTOME-POLYADENYLATION UNVEIL A TREATABLE VITAMIN B1 DEFICIENCY IN HUNTINGTON'S DISEASE
2021-09-050
PRE
Targeting galectin-1 inhibits pancreatic cancer progression by modulating tumor-stroma crosstalk

靶向galectin-1通过调节肿瘤-基质串扰抑制胰腺癌进展

2018-04-04126
OAAI